News

Two-year data suggest the average cost of aflibercept monotherapy was approximately $26, 500 compared with approximately $14, 000 for the bevacizumab-first group in eyes with center-involved DME.

On February 2, Abbott announced their FlexAbility™ Ablation Catheter, Sensor Enabled had received an expanded approval from the US Food and Drug Administration and their TactiFlex™ Ablation Catheter, Sensor Enabled received a CE Mark.

"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.

This week, the FDA announced that 27 lots of levothyroxine sodium oral solution, used for hypothyroidism, were being recalled due to potentially being subpotent.

The FDA and CDC are urging the immediate discontinuation of EzriCare Artificial Tears as they investigates a multistate cluster of potential bacterial contamination.

The same risk was not found for offspring of fathers with primary immunodeficiencies.

A systematic review of nearly 100 published studies provides an overview of sex-based disparities in the care of pediatric patients with type 1 diabetes.

The biologic from Amgen and AstraZeneca was approved for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

In a population-based cohort study in China, researchers found that a healthy lifestyle contributed to slower declines in memory for older adults.

A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.

A recent research letter identified a correlation between mRNA vaccines for COVID-19 and cases of chronic spontaneous urticaria, although the connection requires further study.

The geographic range of practitioner to million persons has increased since 2007, with disparities in practitioner distribution associated with lower socioeconomic status.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.

The statement suggests PCI without surgery on site is as safe as PCI at centers with on-site surgery across randomized controlled trials, observational studies, and international experiences.

Dr. Carolyn Rowley and Pat Corley, RN, explain why the new Sickle Cell Trait Awareness Campaign is designed for all middle school, high school, and university students.

In a recent analysis of 6 trials examining the use of dupilumab, the drug was found to be useful alongside concomitant TCS for patients with erythrodermic atopic dermatitis.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

Using data from more than 2 million US adults with nonsurgical hospitalizations, a new study from the Mayo Clinic is sounding the alarm on the increased cardiovascular risk associated with developing sepsis.

In an effort to address unmet needs related to the accessibility of biosimilars globally, the WHO updates the guidelines to include more therapies in the category.

Sintilimab plus IBI305 showed a significant improvement in objective response rate, time to response, duration of response, and depth of response in unresectable HCC versus sorafenib.

Natalizumab PB006 is the first biosimilar monoclonal antibody developed for treating patients with multiple sclerosis (MS).

There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

An analysis of the UK Biobank suggests individuals with celiac disease had an incidence rate of 9.0 CVD cases per 1000 person years compared with 7.4 per 1000 person years in people with no celiac disease.

Adalimumab-atto will be used to treat several inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.

The FDA announced that Banana Boat Hair & Scalp Sunscreen was being recalled voluntarily by its company due to risk of benzene exposure to consumers.